Jane Street Group LLC Purchases 3,342 Shares of biote Corp. (NASDAQ:BTMD)

Jane Street Group LLC boosted its position in biote Corp. (NASDAQ:BTMD) by 24.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 16,873 shares of the company’s stock after purchasing an additional 3,342 shares during the period. Jane Street Group LLC’s holdings in biote were worth $94,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of biote by 59.0% in the second quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after buying an additional 34,999 shares during the last quarter. Rhumbline Advisers raised its stake in biote by 104.2% in the 2nd quarter. Rhumbline Advisers now owns 28,225 shares of the company’s stock valued at $211,000 after acquiring an additional 14,404 shares during the period. WINTON GROUP Ltd lifted its holdings in biote by 7.0% during the 2nd quarter. WINTON GROUP Ltd now owns 47,725 shares of the company’s stock valued at $357,000 after purchasing an additional 3,124 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in biote by 1,016.6% during the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock worth $4,931,000 after purchasing an additional 600,956 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in shares of biote by 251.8% in the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after purchasing an additional 138,200 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

biote Stock Performance

BTMD opened at $5.67 on Wednesday. The stock has a fifty day moving average of $6.16 and a 200-day moving average of $6.23. The company has a market capitalization of $308.09 million, a P/E ratio of 21.81 and a beta of 1.08. biote Corp. has a fifty-two week low of $3.65 and a fifty-two week high of $8.44.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on shares of biote in a report on Monday, December 16th. They set a “buy” rating and a $12.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $9.11.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.